<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1861">
  <stage>Registered</stage>
  <submitdate>26/02/2008</submitdate>
  <approvaldate>26/02/2008</approvaldate>
  <nctid>NCT00629642</nctid>
  <trial_identification>
    <studytitle>Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple Sclerosis</studytitle>
    <scientifictitle>A Randomized, Double Blind, Double Dummy, Placebo Controlled Study to Evaluate the Efficacy and Safety of Solifenacin Succinate (5 and 10mg Once Daily) Against Placebo and Oxybutynin Hydrochloride (5 mg Three Times Daily) in the Treatment of Subjects With Neurogenic Detrusor Overactivity</scientifictitle>
    <utrn />
    <trialacronym>SONIC</trialacronym>
    <secondaryid>2006-005523-42</secondaryid>
    <secondaryid>905-EC-005</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Multiple Sclerosis</healthcondition>
    <healthcondition>Neurogenic Bladder</healthcondition>
    <healthcondition>Spinal Cord Diseases</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Other renal and urogenital disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Solifenacin Succinate
Treatment: drugs - Solifenacin Succinate
Treatment: drugs - Oxybutynin Hydrochloride
Treatment: drugs - Placebo

Experimental: I.Solifenacin succinate 10mg (2x5mg 1/day) - Oral

Experimental: II.Solifenacin succinate 5mg (5mg 1/day) - Oral

Active Comparator: III.Oxybutynin hydrochloride 15mg (5mg 3/day) - Oral

Placebo Comparator: IV. Placebo - Oral


Treatment: drugs: Solifenacin Succinate
Oral, 10mg

Treatment: drugs: Solifenacin Succinate
Oral, 5mg

Treatment: drugs: Oxybutynin Hydrochloride
Oral, 15mg

Treatment: drugs: Placebo
Oral

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change from baseline in maximum cystometric capacity</outcome>
      <timepoint>4 Weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in bladder volume at first involuntary contraction</outcome>
      <timepoint>4 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in pressure at first leak</outcome>
      <timepoint>4 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in volume at first leak</outcome>
      <timepoint>4 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in maximum detrusor pressure</outcome>
      <timepoint>4 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in micturition or catheterization frequency</outcome>
      <timepoint>4 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in incontinence episodes</outcome>
      <timepoint>4 Weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence and severity of adverse events</outcome>
      <timepoint>4 Weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Written informed consent has been obtained

          -  Subjects with neurogenic detrusor overactivity due to:

               -  Multiple sclerosis(MS)(EDSS=8) or

               -  Spinal cord injury(SCI)(partial or complete lesions)

          -  MS or SCI symptoms should be stable for &gt;= 6 months

          -  Neurogenic detrusor overactivity symptoms should be stable for &gt;= 6 months

          -  Subject is willing and able to perform clean, intermittent, catheterization, if
             required

          -  Subject is willing and able to take study medication in compliance with the protocol</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Subjects with neurogenic detrusor overactivity due to Parkinson's or cerebrovascular
             disease

          -  Subjects with Sj√∂gren's Syndrome or any similar symptoms

          -  Subjects with evidence of a symptomatic urinary tract infection, chronic inflammation
             such as interstitial cystitis, bladder stones, previous pelvic radiation therapy or
             previous or current malignant disease of the pelvic organs

          -  Subjects with stress incontinence or mixed incontinence where stress is the
             predominant factor as determined by the investigator

          -  Subjects with evidence of pressure sores &gt;= grade 2

          -  Subjects with a history of bladder sphincterotomy

          -  Subjects with known history of vesico-ureteral reflux without upper urinary tract
             infection

          -  Any clinically significant condition, which in the opinion of the investigator makes
             the subject unsuitable for the study or includes a history of acute urinary retention,
             severe gastrointestinal obstruction (including paralytic ileus or intestinal atony),
             severe gastrointestinal conditions (including toxic megacolon or ulcerative colitis),
             myasthenia gravis, narrow angle glaucoma or shallow anterior chamber

          -  Subjects undergoing hemodialysis

          -  Subjects with severe hepatic impairment

          -  Concurrent use of drugs intended to treat symptoms of overactive bladder

          -  Use of antidepressants or muscle relaxants which have not been administered at a
             constant dose for &gt;= 3 months

          -  Use of non-drug treatment intended to treat overactive bladder symptoms including
             electrostimulation therapy, botulinum toxin and vanilloids therapy in the six months
             prior to the commencement of the study

          -  Use of permanent, indwelling catheters

          -  Known or suspected hypersensitivity to solifenacin succinate, oxybutynin
             hydrochloride, other anti cholinergics or lactose

          -  Concomitant use of a strong CYP3A4 inhibitor, e.g. ketoconazole

          -  Pregnant women, women who intend to become pregnant during the study, women of
             childbearing potential who are sexually active and practicing an unreliable method of
             birth control or women who will be lactating during the study. Reliable contraceptive
             methods are intra-uterine devices, contraceptive pills of combination type, hormonal
             implants and injectable contraceptives

          -  Participation in any clinical study within 30 days of randomization, or the limit set
             by national law, whichever is longer

          -  Employees of the Astellas Group, third parties associated with the study, or the study
             site

          -  Subjects with maximum bladder capacity &gt;= 400ml at visit 2</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>14/03/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>249</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>28/01/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital> - Brisbane</hospital>
    <hospital> - Melbourne</hospital>
    <hospital> - Perth</hospital>
    <hospital> - Randwick</hospital>
    <postcode> - Brisbane</postcode>
    <postcode> - Melbourne</postcode>
    <postcode> - Perth</postcode>
    <postcode> - Randwick</postcode>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Antwerpen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Esneux</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Fraiture-en-Condroz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Gent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Melsbroek</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Brno</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Ceske Budejovice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Prague</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Caen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Garches</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Ploemeur</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hagenow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Heidelberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Kiel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Nyiregyhaza</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Sopron</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Szeged</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Firenze</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Rome</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Torino</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Apeldoorn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Eindhoven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Nijmegen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>St. Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Alicante</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>La Coruna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Cardiff</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Newcastle Upon Tyne</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Astellas Pharma Inc</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>A clinical study to evaluate the efficacy and safety of solifenacin in patients with bladder
      symptoms due to spinal cord injury or multiple sclerosis</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00629642</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Department of (Neuro) Urology</name>
      <address>Universitaire Ziekenhuizen Leuven</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>